MEDSIR

Excited to announce our partnership with Rui Rui Zhang Xiang, Business Development Director at MEDSIR for the 21st BioPharma Clinical Trials Nexus! 🌟 Join us on October 22nd & 23rd, 2024, at the Holiday Inn Piscataway Somerset, NJ, where industry leaders will converge for unparalleled alliances, collaborations, and partnerships. This is your chance to be part of groundbreaking discussions and innovative solutions in the biopharma space. Don't miss out—register today! 👉 https://lnkd.in/dSz-gc7c #ClinicalTrials #BioPharma #Partnerships #MEDSIR #Innovation #Biotech #Pharma #Networking #Collaboration #Nexus2024

Tumors of the central nervous system (CNS), especially brain metastasis (BMs) and leptomeningeal disease (LMD), pose significant challenges in clinical oncology due to their complex nature and limited treatment options. The recent SNO/ASCO CNS Metastases Conference emphasized the urgent need for innovative therapies. We presented the final results of the #DEBBRAHtrial, showcasing the efficacy of trastuzumab deruxtecan (T-DXd) in treating HER2-positive and HER2-low advanced breast cancer patients with BMs and LMD. This groundbreaking study, involving 41 patients across Spain and Portugal, demonstrated promising outcomes, including a 16-week progression-free survival rate of 87.5% in Cohort 1 and impressive intracranial response rates in other cohorts. These findings highlight the importance of including patients with untreated or progressing BMs and LMD in clinical trials. We are excited to share these results and continue our commitment to advancing cancer treatment. Read the full article: https://lnkd.in/d9sP2uec Discover more about DEBBRAH study:https://lnkd.in/d27SMZHe #SNOASCO24 #CancerResearch *** Tuvimos el honor de participar en la SNO/ASCO CNS Metastases Conference, donde presentamos los resultados finales del estudio DEBBRAH. Este estudio evalúa la eficacia de trastuzumab deruxtecan en pacientes con cáncer de mama avanzado HER2+ y HER2-bajo con metástasis cerebrales o carcinomatosis leptomeníngea, mostrando prometedores avances en el tratamiento de estas complejas condiciones.

MEDSIR at #SNOASCO24 ! We were excited to participate in SNO/ASCO Brain Metastases for the first time where we presented all five cohorts of the #DEBBRAHstudy! This phase II clinical trial evaluated the antitumor activity of trastuzumab deruxtecan for patients with HER2-positive and HER2-low advanced breast cancer with brain metastases or leptomeningeal carcinomatosis. The results of this study address the high unmet need in these difficult-to-treat conditions. Poster OCTS-03 - A multicenter, open-label, single-arm, multicohort phase II clinical trial of trastuzumab deruxtecan in human epidermal growth factor receptor 2 (HER2)-positive and HER2-low advanced breast cancer (ABC) with brain metastases and/or leptomeningeal carcinomatosis (LMC) – The DEBBRAH study Presented by: Eileen Shimizu, PhD Download the poster here: https://lnkd.in/dFhkgpua Download the Lay Language Summary: https://lnkd.in/dDdc-T5X ***** Este ensayo clínico de fase II evaluó la actividad antitumoral de trastuzumab deruxtecan en pacientes con cáncer de mama avanzado con HER2 positivo o HER2 bajo con metástasis cerebrales o carcinomatosis leptomeníngea. Los resultados de este estudio abordan la gran necesidad insatisfecha en estas afecciones difíciles de tratar.

We’re thrilled to announce the publication of a commentary by Dr. Xavier García del Muro, on the #ORPHEUStrial “Retifanlimab in Advanced Penile Squamous Cell Carcinoma: The Phase 2 ORPHEUS Study, published in UroToday + GU OncToday ! This study evaluated the efficacy and safety of Retinfalimab in Advanced Penile Squamous Cell Carcinoma, exploring the potential of Retifanlimab as an innovative treatment option that could significantly improve the lives of patients battling this challenging condition. At MEDSIR, we are committed to pushing the boundaries of medical research and finding new, effective solutions for complex diseases. The ORPHEUS Study represents a major step forward in our mission to bring cutting-edge therapies to those who need them most. Read the publication: https://lnkd.in/d647WrPs Find more information about the ORPHEUS clinical trial: https://lnkd.in/dacr8T-t ******************** ¡Un cometario del #ORPHEUStrial "Retifanlimab en Carcinoma Avanzado de Células Escamosas del Pene: El Estudio ORPHEUS de Fase 2" ha sido publicado en UroToday + GU OncToday ! Este estudio explora el potencial de Retifanlimab como una opción de tratamiento innovadora que podría mejorar significativamente la vida de los pacientes que enfrentan esta difícil condición. #Urology #Innovation #Healthcare #Oncology

Yesterday kicked off the CNS Metastases Conference hosted by Society for Neuro-Oncology and American Society of Clinical Oncology (ASCO) in Denver, Colorado. As we begin #SNOASCO24, look forward to a blend of scientific insights and collaborative opportunities! Feel free to reach out to us and stay updated! ****** Hoy comienza la Conferencia sobre Metástasis del CNS organizada por la ociety for Neuro-Oncology y la American Society of Clinical Oncology (ASCO) en Denver, Colorado Al comenzar #SNOASCO24, esperamos una combinación de conocimientos científicos y oportunidades de colaboración. ¡No dudes en contactarnos!

Exciting News! Another recognition for the #PHERGain trial, this time for the exploratory analysis " HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial" in collaboration with REVEAL GENOMICS, S.L. #HER2DX® is a prognostic, predictive assay based on clinical and genomic data. The test integrates clinical information (e.g., tumor size and nodal status) with biological information tracking immune response, luminal differentiation, tumor cell proliferation, and expression of the HER2 17q12-21 chromosomal amplicon, including the ERBB2 gene. Learn more about the study: https://lnkd.in/d2qUv8vE You can access the publication here: https://lnkd.in/d5nrrnir #CancerReseacrh #ClinicalTrials #Oncology *** HER2DX® es un ensayo pronóstico y predictivo basado en datos clínicos y genómicos. Esta prueba integra información clínica con información biológica, proporcionando un enfoque integral para el tratamiento del cáncer de mama HER2+ en etapa temprana. Comercializada por REVEAL GENOMICS, S.L. desde enero de 2022, HER2DX® es una prueba estandarizada de expresión de 27 genes diseñada específicamente para pacientes con este tipo de cáncer. Con esta herramienta, se busca mejorar la precisión en la predicción del pronóstico y en la personalización del tratamiento para estos pacientes.

In the last 20 years, technology has improved medicine in many aspects, but it seems that the implementation of AI in clinical trials is limited due to the complexity of these studies. However, AI has great potential in clinical research and oncology. This year, Medsir presented the MIRROR study at the 22nd International Conference on Artificial Intelligence in Medicine #AIME2024   The #MIRRORstudy, in collaboration with Hospital Universitario Virgen del Rocío and Science4Tech, compares whether AI-extracted data from electronic health records (EHRs) matches manually collected data in electronic Case Report Forms (eCRFs) from previous clinical trials. The results show significant effectiveness: almost 80% in the extraction of most clinical variables, especially standardized data, for 113 breast cancer patients at Hospital Virgen del Rocío between 2012 and 2021. The study highlights the potential of AI to automate data extraction in clinical trials.   Being part of this project and presenting at AIME was a great honor, and we would like to especially thank Daniel Alcalá López, PhD, Data Science Expert at MEDSIR, for presenting this study within the scientific community.  Read the article: https://lnkd.in/dw4KGsFZ     #Innovation #ClinicalResearch **** El #MIRRORstudy, en colaboración con el Hospital Universitario Virgen del Rocío y Science4Tech, compara si los datos extraídos por IA de registros médicos electrónicos (EHR) coinciden con los datos recopilados manualmente en formularios electrónicos de informes de casos (eCRF) de ensayos clínicos anteriores. Los resultados muestran una efectividad significativa: casi el 80% en la extracción de la mayoría de variables clínicas, especialmente datos estandarizados, para 113 pacientes con cáncer de mama en el Hospital Virgen del Rocío entre 2012 y 2021. El estudio destaca el potencial de la IA para automatizar la extracción de datos en ensayos clínicos.

#MEDSIRatAIME We have presented the results poster of the  #MIRRORstudy in collaboration with Hospital Universitario Virgen del Rocío and Science4tech! The goal of the MIRROR study is to validate the use of artificial intelligence (AI) for data capture in clinical trials, comparing whether AI-extracted data from electronic health records (EHRs) matches manually collected data in electronic Case Report Forms (eCRFs) from previous clinical trials.   Poster P30 - Evaluation of a Generative Artificial Intelligence and Natural Language Processing tool to obtain clinical data from electronic health records versus manual data capture in Oncology Clinical Trials: The MIRROR study. Presented by: Daniel Alcalá López Download the poster here: https://lnkd.in/dS3uU3yC Download the Lay Language Summary: https://lnkd.in/dXFPDvTV ***** El objetivo del estudio MIRROR es validar el uso de inteligencia artificial (IA) para la captura de datos en ensayos clínicos, comparando si los datos extraídos por IA de registros médicos electrónicos (EHR) coinciden con los datos recopilados manualmente en formularios electrónicos de informes de casos (eCRF) de ensayos clínicos previos.

Today marks the commencement of the AIME -Artificial Intelligence in Medicine Congress, in Utah. As we embark at #AIME2024, expect a convergence of scientific insights and collaborative opportunities. Don't hesitate to contact us and stay tuned for updates! ****** Hoy marca el inicio del Congreso de Inteligencia Artificial en Medicina, AIME, en Utah. Mientras nos embarcamos en #AIME2024, esperen una convergencia de conocimientos científicos y oportunidades de colaboración. ¡No dudéis en contactarnos y manteneros atentos a las actualizaciones!

Join us at #AIME24 Exciting news awaits! Our team is thrilled to announce their presence at the AIME - Artificial Intelligence in Medicine Congress hosted by the University of Utah, taking place on 9-12 July 2024 in Salt Lake City, Utah! We will present our MIRROR study: "Evaluation of a Generative Artificial Intelligence (#AI) and Natural Language Processing (NLP) tool to obtain clinical data from electronic health records (EHRs) versus manual data capture in Oncology Clinical Trials: The MIRROR study". This study has been conducted in collaboration with Hospital Universitario Virgen del Rocío in Seville and Science4Tech. Don't miss this opportunity to engage with us! https://lnkd.in/dGmp9yJZ #ClinicalTrials #ArtificialIntelligenceInMedicine #OncologyResearch *** ¡Grandes notícias! Nuestro equipo está encantado de anunciar su presencia en el AIME, el Congreso de Inteligencia Artificial en Medicina que tendrá lugar del 9 al 12 de julio de 2024 en Salt Lake City, Utah, presentando nuestro estudio MIRROR !